All In MedTech

FDA Clearance Tracker · K202830

Axiostat Patch

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Apr 15, 2021 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Apr 15, 2021

Substantially Equivalent

Time to decision

202 days

Received Sep 25, 2020. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Unclassified

The decision

FDA number
K202830
Device name
Axiostat Patch
Applicant location
Cambridge, MA
Received
Sep 25, 2020
Decided
Apr 15, 2021
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Unclassified

Every decision under product code QSY

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code QSY. The earliest in FDA's data is K893123, decided Feb 13, 1990.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Advamedica, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.